Journal of the American Chemical Society · 2014 · 45 citations · 30 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryOrganic ChemistryStructure-activity RelationshipsNatural Product Drug DiscoveryOrganic SynthesisPeptide ChemistryRetrosynthetic AnalysisStructure-activity Relationship AnalysisAbsolute Configuration AssignmentAbsolute Configuration DeterminationAnticancer ActivityAnticancer ChemotherapyConfiguration At Chiral CentersStereochemical AssignmentStereochemical DiversityStereochemical Structure-activity Relationships
Rakicidin A is a cyclic depsipeptide that has exhibited unique growth inhibitory activity against chronic myelogenous leukemia stem cells. Furthermore, rakicidin A has five chiral centers with unknown stereochemical assignment, and thus, can be represented by one of 32 possible stereoisomers. To predict the most probable stereochemistry of rakicidin A, calculations and structural comparison with natural cyclic depsipeptides were applied. A total synthesis of the proposed structure was subsequently completed and highlighted by the creation of a sterically hindered ester bond (C1-C15) through trans-acylation from an easily established isomer (C1-C13). The analytic data of the synthetic target were consistent with that of natural rakicidin A, and then the absolute configuration of rakicidin A was assigned as 2S, 3S, 14S, 15S, 16R. This work suggests strategies for the determination of unknown chiral centers in other cyclic depsipeptides, such as rakicidin B, C, D, BE-43547, and vinylamycin, and facilitates the investigations of rakicidin A as an anticancer stem cell agent.
30
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta, Tamer T. Önder, Guozhi Jiang et al. · Cell · 2009 · 2.4K citations · Full text
Roots and stems: stem cells in cancer
Kornélia Polyák, William C. Hahn · Nature Medicine · 2006 · 371 citations